Get started
Author

S. A. Wander

Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer
2026 · S. A. Wander, C. M. Weipert, et al. · npj Breast Cancer · 1
PDF
Abstract PS1-11-07: First-in-human, phase 1a/b study of GDC-4198 (RGT-419B), a next generation CDK4/2 inhibitor, in patients with hormone receptor positive HER2- locally advanced/metastatic breast cancer (LA/mBC) who progressed on prior CDK4/6 inhibitors
2026 · S. A. Wander, R. Zuniga, et al. · Clinical Cancer Research · 1
Abstract PS1-11-15: Current and future use of oral selective estrogen receptor degraders (SERDs) in the management of ER-positive (ER+), HER2-negative (HER2-neg) metastatic breast cancer (mBC): A survey of 20 breast cancer research leaders (RLs)
2026 · K. H. Pang, K. A. Ziel, et al. · Clinical Cancer Research · 1
Abstract PS2-11-28: Gdc-4198, a next-generation CDK4/2 inhibitor, induces durable cell cycle arrest and overcomes CDK2-driven adaptation to CDK4 inhibition
2026 · M. Hafner, S. Vartanian, et al. · Clinical Cancer Research · 1
Abstract PS1-08-28: The use of oral selective estrogen receptor degraders (SERDs) by community-based general medical oncologists (GMOs) in ER-positive (ER+), HER2-negative (HER2-neg) metastatic breast cancer (mBC): A clinician survey of practice patterns and practical challenges
2026 · K. H. Pang, K. A. Ziel, et al. · Clinical Cancer Research · 1
Abstract PS2-07-02: Tissue-free epigenomic circulating tumor DNA (ctDNA) analysis pre- and post-surgery in early breast cancer: clinical features and prognostic utility
2026 · A. J. Medford, J. Knape, et al. · Clinical Cancer Research
Abstract PS1-08-15: Dauntless-1: A Phase 2 Clinical Trial to Evaluate PMD-026, a First-in-Class Pan-RSK Inhibitor, Combined with Fulvestrant to Overcome Resistance to CDK4/6 Inhibitors in Advanced or Metastatic HR+/HER2- Breast Cancer
2026 · H. T. Khong, M. Beeram, et al. · Clinical Cancer Research
Abstract PS4-02-20: Clinical and genomic biomarkers of capivasertib response in patients with hormone receptor-positive, HER2-negative metastatic breast cancer (HR+/HER2- MBC)
2026 · M. R. Lloyd, E. L. Podany, et al. · Clinical Cancer Research
Abstract PS5-07-30: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation
2026 · M. P. Goetz, S. A. Wander, et al. · Clinical Cancer Research
Abstract PS1-10-17: Progression-free Survival by Local Investigators vs. Blinded Independent Central Review in Hormone-Positive, HER2-Negative Metastatic Breast Cancer: A Systematic Review and Meta-analysis
2026 · L. Ravani, Z. Bagheri, et al. · Clinical Cancer Research
Abstract PS2-08-17: Prevalence and clinical significance of exon 6 ESR1 gene fusions in advanced breast cancer after disease progression on aromatase inhibitors
2026 · S. A. Wander, D. G. Stover, et al. · Clinical Cancer Research
Abstract PS2-10-21: Associations Between Circulating Tumor DNA Genomic Profiles and Serum Thymidine Kinase Patterns in Patients with Advanced, Hormone Receptor-Positive, HER2-Negative (HR+/HER-) Breast Cancer Initiating Treatment with a CDK4/6 Inhibitor (CDK4/6i)
2026 · E. M. Michaels, N. A. Bagegni, et al. · Clinical Cancer Research
Abstract PS2-07-24: Circulating tumor DNA (ctDNA) biomarker analyses of a phase 1/2 study evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (aBC)
2026 · S. A. Wander, H. S. Han, et al. · Clinical Cancer Research
Works count: 13
Citation count: 5
H-index: 1
I10-index:
Year
Topic
Type